# Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

> **NCT01055821** · PHASE2 · COMPLETED · sponsor: **Transgene** · enrollment: 140 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** pegylated interferon and ribavirin
- **BIOLOGICAL:** TG4040 + SOC
- **BIOLOGICAL:** TG4040 + SOC

## Key facts

- **NCT ID:** NCT01055821
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-10
- **Final completion:** 2013-08
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2013-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01055821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01055821, "Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01055821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*